338 related articles for article (PubMed ID: 16182378)
1. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
[TBL] [Abstract][Full Text] [Related]
2. CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis.
Kaimen-Maciel DR; Reiche EM; Brum Souza DG; Frota Comini ER; Bobroff F; Morimoto HK; Ehara Watanabe MA; Carvalho De Oliveira J; Matsuo T; Lopes J; Donadi EA
Int J Mol Med; 2007 Sep; 20(3):337-44. PubMed ID: 17671738
[TBL] [Abstract][Full Text] [Related]
3. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
[TBL] [Abstract][Full Text] [Related]
4. The role of the CCR5 Delta32 polymorphism in abdominal aortic aneurysms.
Sandford B; Bown M; London N; Sayers R
Int J Immunogenet; 2009 Aug; 36(4):199-205. PubMed ID: 19476483
[TBL] [Abstract][Full Text] [Related]
5. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis.
Eri R; Jonsson JR; Pandeya N; Purdie DM; Clouston AD; Martin N; Duffy D; Powell EE; Fawcett J; Florin TH; Radford-Smith GL
Genes Immun; 2004 Sep; 5(6):444-50. PubMed ID: 15215889
[TBL] [Abstract][Full Text] [Related]
6. Chemokine receptor CCR5 in interferon-treated multiple sclerosis.
Sellebjerg F; Kristiansen TB; Wittenhagen P; Garred P; Eugen-Olsen J; Frederiksen JL; Sørensen TL
Acta Neurol Scand; 2007 Jun; 115(6):413-8. PubMed ID: 17511851
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
8. The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients.
Kohem CL; Brenol JC; Xavier RM; Bredemeier M; Brenol CV; Dedavid e Silva TL; de Castilhos Mello A; Cañedo AD; Neves AG; Chies JA
Scand J Rheumatol; 2007; 36(5):359-64. PubMed ID: 17963165
[TBL] [Abstract][Full Text] [Related]
9. The 32-base pair deletion of the chemokine receptor 5 gene (CCR5-Delta32) is not associated with primary sclerosing cholangitis in 363 Scandinavian patients.
Melum E; Karlsen TH; Broomé U; Thorsby E; Schrumpf E; Boberg KM; Lie BA
Tissue Antigens; 2006 Jul; 68(1):78-81. PubMed ID: 16774544
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the CC chemokine receptor 5 delta32 polymorphism in a Brazilian population with cutaneous leishmaniasis.
Brajão de Oliveira K; Reiche EM; Kaminami Morimoto H; Pelegrinelli Fungaro MH; Estevão D; Pontello R; Franco Nasser T; Watanabe MA
J Cutan Pathol; 2007 Jan; 34(1):27-32. PubMed ID: 17214851
[TBL] [Abstract][Full Text] [Related]
11. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility.
Srivastava A; Pandey SN; Choudhuri G; Mittal B
Scand J Immunol; 2008 May; 67(5):516-22. PubMed ID: 18405329
[TBL] [Abstract][Full Text] [Related]
12. Genetic variations in CC chemokine receptors and hypertension.
Zhang M; Ardlie K; Wacholder S; Welch R; Chanock S; O'Brien TR
Am J Hypertens; 2006 Jan; 19(1):67-72. PubMed ID: 16461193
[TBL] [Abstract][Full Text] [Related]
13. Frequency of CCR5-Delta32 deletion in human immunodeficiency virus type 1 (HIV-1) in healthy blood donors, HIV-1-exposed seronegative and HIV-1-seropositive individuals of southern Brazilian population.
Reiche EM; Ehara Watanabe MA; Bonametti AM; Morimoto HK; Akira Morimoto A; Wiechmann SL; Matsuo T; Carvalho De Oliveira J; Vissoci Reiche F
Int J Mol Med; 2008 Nov; 22(5):669-75. PubMed ID: 18949389
[TBL] [Abstract][Full Text] [Related]
14. The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
Møller M; Søndergaard HB; Koch-Henriksen N; Sorensen PS; Sellebjerg F; Oturai AB
Acta Neurol Scand; 2014 Jan; 129(1):27-31. PubMed ID: 23668375
[TBL] [Abstract][Full Text] [Related]
15. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex.
van Rij RP; Portegies P; Hallaby T; Lange JM; Visser J; de Roda Husman AM; van 't Wout AB; Schuitemaker H
J Infect Dis; 1999 Sep; 180(3):854-7. PubMed ID: 10438379
[TBL] [Abstract][Full Text] [Related]
16. [Effects of CCR5-delta32, CCR2-64I and SDF-1-3'A polymorphic alleles on human immunodeficiency virus 1 (HIV-1) infection in the Polish population].
Wasik TJ; Smoleń J; Kruszyński P; Bratosiewicz-Wasik J; Beniowski M
Wiad Lek; 2005; 58(9-10):500-7. PubMed ID: 16529059
[TBL] [Abstract][Full Text] [Related]
17. CCR2-64I polymorphism and CCR5Delta32 deletion in patients with Alzheimer's disease.
Galimberti D; Fenoglio C; Lovati C; Gatti A; Guidi I; Venturelli E; Cutter GR; Mariani C; Forloni G; Pettenati C; Baron P; Conti G; Bresolin N; Scarpini E
J Neurol Sci; 2004 Oct; 225(1-2):79-83. PubMed ID: 15465089
[TBL] [Abstract][Full Text] [Related]
18. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
[TBL] [Abstract][Full Text] [Related]
19. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
Vázquez-Lavista LG; Lima G; Gabilondo F; Llorente L
Urology; 2009 Aug; 74(2):414-8. PubMed ID: 19646633
[TBL] [Abstract][Full Text] [Related]
20. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
